In this discussion, Tiffany Phung, Pharm.D., CSP, director of specialty pharmacy value, trade relations and market access at UC Davis Health, explores the challenges facing health system specialty pharmacies and how data-driven collaboration is shaping the future of patient care.
Part D enrollment has shifted: standalone plan offerings are down 22%, while special needs plans grew 21%, reshaping competition among fewer, larger sponsors nationally, finds an analysis by IPD Analytics.
Luis Ortiz, M.D., of Johns Hopkins All Children's Hospital, explains the subtle signs of childhood narcolepsy that parents often overlook.
Pediatric sleep specialist Luis Enrique Ortiz, M.D., opens up about living with Type 1 narcolepsy with cataplexy, the long road to diagnosis and how the condition has shaped both his career and personal life.
Medicare’s GLP-1 Bridge program offers eligible Part D beneficiaries select GLP-1s for weight loss at $50/month, outside Part D, pending BALANCE model.
Shingrix (recombinant shingles vaccine) links to 9% lower cardiovascular disease burden in older adults over seven years, strengthening vaccination value beyond shingles prevention.
A Swedish registry study of 58,641 patients found lower education levels were linked to higher mortality after hip fracture surgery.
A University of Pennsylvania study found that GLP-1 users with Type 2 diabetes had 37% to 68% higher hair loss rates than patients taking other diabetes medications.
A Johns Hopkins trial found low-dose hydrocortisone improved attention and verbal learning in women with HIV, with gains sustained over several weeks.
University of Utah Health researchers have shown that a protein involved in cancer growth also plays a role in whether a fatty liver progresses to MASH.
Mimrylo is available now to treat adults with polycythemia vera, a blood cancer that causes the overproduction of red blood cells. It has a list price of $4,200 per vial.
As artificial intelligence agents learn to improve autonomously, the humans who must use and regulate such tools find themselves behind the curve.
Funding from the Rural Health Transformation Program is beginning to flow to the states. The purpose is larger, but some say its success should be measured by whether it preserves access to care at rural hospitals.
VESALIUS-CV shows Repatha (evolocumab) cuts all-cause death 20% in high-risk CVD patients, preventing future stroke and heart attack.
Mounjaro is now approved for two indications: to improve blood sugar in patients with Type 2 diabetes and to lower the major adverse cardiovascular events.
JAMA Health Forum finds Medicare Advantage members with new complex diagnoses increasingly switch to traditional Medicare, highlighting MediGap barriers, state protections, and plan limits.
People may not be fully aware of added cost exposures if they shift to bronze Affordable Care (ACA) plans, says Margaret A. Murray, M.P.A., CEO of the Association for Community Health Plans. Murray says the nonnetwork plans that the Trump administration is promoting will result in underinsurance.
Gilead's Bixlenvo, the smallest once-daily HIV pill yet, has been approved by the FDA for virologically suppressed adults on complex regimens.
University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict monthly risk of nine acute and chronic complications.
Brepocitinib, now with the brand name Lisraya, treats adults with dermatomyositis, rare autoimmune disease. It is available now, but Priovant Therapeutics has not provided a list price.
Eli Lilly’s Zepbound real-world study shows older adults with obesity cut non-drug healthcare costs 25% via fewer hospital and ER visits, informing Medicare coverage.
In a wide-ranging interview, the CEO of the Association for Community Affiliated Plans (ACAP) discusses Medicaid enrollment, Medicaid work requirements, the ACA marketplace plan, her 25 years at the helm of ACAP and whether she is burnt out.
Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says outreach and texting will be key to keeping eligible Medicaid enrollees covered under new redetermination and work requirements.
A phase 3 trial of intravenous arginine was stopped early after it did not meaningfully shorten acute pain sickle cell crises' recovery time.
A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients saved $39.50 in monthly out-of-pocket costs.
Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says ACAP opposes Medicaid work requirements but seeks common ground with CMS on issues such as program integrity.
A pilot combining AI screening with structured nodule follow-up found early lung cancer in 1.6% of flagged patients.
The FDA approved ViiV Healthcare's Tivicay PD for children weighing at least 2 kg, making it the first second-generation HIV integrase inhibitor for this group.
Tevimbra plus Ziihera with chemo raises survival in first-line HER2-positive gastroesophageal cancer, offering a new FDA-approved option.
Rasonque (daraxonrasib) was approved more than six months ahead of its PDUFA date. It has a wholesale acquisition cost of $39,800 for a 30-day supply.
